Dolutegravir is an increasingly-used second-generation human immunodeficiency virus integrase strand transfer inhibitor. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome has been described in several patients treated with raltegravir but to our knowledge, there is no previous report of DRESS syndrome associated with dolutegravir.
CurtisLet al.
Dolutegravir: clinical and laboratory safety in integrase inhibitor-naive patients. HIV Clin Trials2014;
15: 199–208.
2.
RipamontiDBenattiSVDi FilippoEet al.
Drug reaction with eosinophilia and systemic symptoms associated with raltegravir use: case report and review of the literature. AIDS2014;
28: 1077–1079.
3.
ThomasMHopkinsCDuffyEet al.
Association of the HLA-B*53:01 allele with drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome during treatment of HIV infection with raltegravir. Clin Infect Dis2017;
64: 1198–1203.
4.
CacoubPMusettePDescampsVet al.
The DRESS syndrome: a literature review. Am J Med2011;
124: 588–597.
5.
IchaiPet al.
Acute liver failure/injury related to drug reaction with eosinophilia and systemic symptoms: outcomes and prognostic factors. Transplantation2017;
101: 1830–1837.
